Találati lista | Tudóstér

001-es BibID:	BIBFORM099767
035-os BibID:	(WoS)000737102800002 (Scopus)85122267234
Első szerző:	Llanaj, Erand (táplálkozási epidemiológus)
Cím:	Effect of oat supplementation interventions on cardiovascular disease risk markers : a systematic review and meta-analysis of randomized controlled trials / Llanaj Erand, Dejanovic Gordana M., Valido Ezra, Bano Arjola, Gamba Magda, Kastrati Lum, Minder Beatrice, Stojic Stevan, Voortman Trudy, Marques-Vidal Pedro, Stoyanov Jivko, Metzger Brandon, Glisic Marija, Kern Hua, Muka Taulant
Dátum:	2022
ISSN:	1436-6207
Megjegyzések:	Purpose Oat supplementation interventions (OSIs) may have a beneficial effect on cardiovascular disease (CVD) risk. However, dietary background can modulate such effect. This systematic review assesses the effects of OSIs on CVD risk markers among adults, accounting for different dietary backgrounds or control arms. Methods We included randomized clinical trials (RCTs) that assessed the effect of oat, oat beta-glucan-rich extracts or avenanthramides on CVD risk markers. Results Seventy-four RCTs, including 4937 predominantly hypercholesterolemic, obese subjects, with mild metabolic disturbances, were included in the systematic review. Of these, 59 RCTs contributed to the meta-analyses. Subjects receiving an OSI, compared to control arms without oats, had improved levels of total cholesterol (TC) [weighted mean difference and (95% CI) - 0.42 mmol/L, (- 0.61; - 0.22)], LDL cholesterol [- 0.29 mmol/L, (- 0.37; - 0.20)], glucose [- 0.25 nmol/L, (- 0.36; - 0.14)], body mass index [- 0.13 kg/m(2), (- 0.26; - 0.01)], weight [- 0.94 kg, (- 1.84: - 0.05)], and waist circumference [- 1.06 cm, (- 1.85; - 0.27)]. RCTs on inflammation and/or oxidative stress markers were scarce and with inconsistent findings. RCTs comparing an OSI to heterogeneous interventions (e.g., wheat, eggs, rice, etc.), showed lowered levels of glycated haemoglobin, diastolic blood pressure, HDL cholesterol and apolipoprotein B. The majority of included RCTs (81.1%) had some concerns for risk of bias. Conclusion Dietary OSIs resulted in lowered levels of blood lipids and improvements in anthropometric parameters among participants with predominantly mild metabolic disturbances, regardless of dietary background or control. Further high-quality trials are warranted to establish the role of OSIs on blood pressure, glucose homeostasis and inflammation markers.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	European Journal Of Nutrition. - 61 : 4 (2022), p. 1749-1778. -
További szerzők:	Dejanovic, Gordana M. Valido, Ezra Bano, Arjola Gamba, Magda Kastrati, Lum Minder, Beatrice Stojic, Stevan Voortman, Trudy Marques-Vidal, Pedro Stoyanov, Jivko Metzger, Brandon Glisic, Marija Kern, Hua Muka, Taulant
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM106086
035-os BibID:	(cikkazonosító)1 (WOS)000908911400001 (Scopus)85145920793
Első szerző:	Valido, Ezra
Cím:	Systematic Review of Human and Animal Evidence on the Role of Buckwheat Consumption on Gastrointestinal Health / Valido Ezra, Stoyanov Jivko, Gorreja Frida, Stojic Stevan, Niehot Christa, Kiefte-de Jong Jessica, Llanaj Erand, Muka Taulant, Glisic Marija
Dátum:	2023
ISSN:	2072-6643
Megjegyzések:	Background: Buckwheat is a commonly cultivated crop with growing evidence that it is beneficial to gastrointestinal (GI) health. This systematic review summarizes the role of buckwheat in modifying GI health outcomes and microbiomes. Methods: Four medical databases and Google Scholar were systematically searched. Clinical trials, observational studies, animal in vivo, and in vitro studies with human and animal GI-derived samples were included. Results: There were 32 studies (one randomized controlled trial [RCT], one non-randomized trial, 3 observational, 9 in vitro, and 18 animal in vivo studies) included. In preclinical studies, buckwheat extracts were observed to have cytotoxic potential against human-derived GI cancer cell lines. Animals fed with buckwheat had lower GI mucosal inflammation, higher alpha diversity in the GI microbiome, and higher levels of fecal short-chain fatty acids. Human evidence studies and clinical trials were limited and predominantly of moderate risk of bias. The majority of in vitro studies with GI-derived samples and in vivo studies were reliable without restrictions in study design. Conclusion: In vivo and in vitro studies show that buckwheat may have potential GI benefits due to its anti-oxidant and anti-inflammatory potential; however, human evidence remains limited, and its impact on health in humans remains to be elucidated in future trials.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk buckwheat Tartary buckwheat gastrointestinal symptoms microbiome
Megjelenés:	Nutrients. - 15 : 1 (2023), p. 1-18. -
További szerzők:	Stoyanov, Jivko Gorreja, Frida Stojic, Stevan Niehot, Christa D. Kiefte-de Jong, Jessica Llanaj, Erand (1988-) (táplálkozási epidemiológus) Muka, Taulant Glisic, Marija
Pályázati támogatás:	NA Other
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: